Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) has issued an update.
Paradigm Biopharmaceuticals Ltd. has issued 97,360,143 new securities, which are options expiring on February 11, 2026, as part of a previously announced transaction. This new issuance indicates Paradigm’s ongoing efforts to enhance its financial position and strategic flexibility in the pharmaceutical sector.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. operates within the pharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company primarily deals with treatments that address unmet medical needs and is listed on the Australian Securities Exchange (ASX).
YTD Price Performance: 16.48%
Average Trading Volume: 3,274
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $121.8M
See more data about PAR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue